DCC constrains tumour progression via its dependence receptor activity

Marie Castets1, Laura Broutier, Yann Molin

  • 1Apoptosis, Cancer and Development Laboratory - Equipe labellisée La Ligue, LabEx DEVweCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008 Lyon, France.

Nature
|December 14, 2011
PubMed

Insights

The deleted in colorectal carcinoma (DCC) protein suppresses tumors by inducing cancer cell death. Loss of DCC

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The role of deleted in colorectal carcinoma (DCC) as a tumor suppressor is debated.
  • DCC gene expression is reduced in advanced colorectal cancers.
  • DCC acts as a dependence receptor, inducing apoptosis unless bound by netrin-1.

Purpose of the Study:

  • To investigate the role of DCC-induced apoptosis in tumor progression.
  • To determine if DCC loss-of-function predisposes to aggressive cancer development.
  • To create a mouse model silencing DCC's pro-apoptotic activity.

Main Methods:

  • Genetic silencing of DCC's pro-apoptotic activity in mice.
  • Observation of spontaneous intestinal neoplasia.
  • Assessment of intestinal tumor number and aggressiveness in an APC mutant context.

Main Results:

  • Loss of DCC-induced apoptosis leads to spontaneous intestinal neoplasia at low frequency.
  • DCC loss-of-function increases intestinal tumor number and aggressiveness in APC mutant mice.
  • Development of highly invasive adenocarcinomas observed.

Conclusions:

  • DCC functions as a tumor suppressor by triggering tumor cell apoptosis.
  • DCC-induced apoptosis plays a critical role in controlling tumor progression.
  • Loss of DCC's apoptotic function contributes to colorectal cancer development and aggressiveness.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...